News & Events

The Firm is representing J.P. Morgan Securities LLC and Evercore Partners as financial advisors to Sanofi-Aventis in its acquisition of Genzyme for $74 per share in cash, a transaction valued at approximately $20.1 billion.

In addition to the cash payment, each Genzyme shareholder will receive one Contingent Value Right (CVR) for each share they own, entitling the holder to receive additional cash payments if specified milestones related to certain Genzyme products are achieved. The transaction is expected to close early in the second quarter of 2011, subject to customary closing conditions.

Sanofi-Aventis, which initially launched an unsolicited proposal to acquire Genzyme in October 2010, is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Genzyme is one of the world’s leading biotechnology companies, with many established products and services helping patients in approximately 100 countries.

The Simpson Thacher team includes Casey Cogut, Eric Swedenburg, Jason Breen and Ariel Oxman.